Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs

Journal of Nuclear Cardiology

Volumn 19, Issue 2, 2012, Pages 377-388

  Jiji, Ronny S ^a   Kramer, Christopher M ^a   Salerno, Michael ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Cardiotoxicity; Chemotherapy; Imaging; Non invasive

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; LIPOCORTIN 5; PACLITAXEL; TRASTUZUMAB;

APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HIGH RISK PATIENT; HUMAN; MITRAL VALVE REGURGITATION; MOLECULAR IMAGING; MULTIPLE CYCLE TREATMENT; NON INVASIVE PROCEDURE; NONHUMAN; PAPILLARY MUSCLE DYSSYNCHRONY; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCINTIANGIOGRAPHY; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTINEOPLASTIC AGENTS; HEART DISEASES; HUMANS; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84863471132     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-012-9512-2     Document Type: Review

References (104)

1. Horenstein MS, Vander Heide RS, L'Ecuyer TJ. Molecular basis of anthracycline-induced cardiomyopathy and its prevention. Mol Genet Metab 2000;71:436-44.
2. Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: The critical role of energetics. J Mol Cell Cardiol 2006;41:389-405. (Pubitemid 44362995)
3. Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-7. (Pubitemid 10218041)
4. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, et al. NAD(P)H oxidase and multidrug resistance protein polymorphisms are associated with doxorubicin-induced cardiomyopathy. Circulation 2005;112:3754-62. (Pubitemid 43739516)
5. Minotti G, Saponiero L, Licata S, Menna P, Calafiore AM, Teodori G, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001;7:1511-5. (Pubitemid 32708613)
6. Myrehaug S, Pintilie M, Tsang R, Mackenzie R, Crump M, Chen Z, et al. Cardiac morbidity following modern treatment for Hodgkin's lymphoma: Supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486-93.
7. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672-7.
8. Hudis C. Traztuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
9. Crone SA, Zhao Y, Fan L, Gu Y, Minamisawa S, Liu Y, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65. (Pubitemid 34546747)
10. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:784-92.
11. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B, Goldhirsch A, Untuch M, Smith I, et al. Traztuzumab after adjunctive chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-71.
12. Yoon GJ, Telli ML, Kao DP, Matsuda KY, Carlson RW, Witteles RM. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies. Are clinicians responding optimally? J Am Coll Cardiol 2010;56:1644-50.
13. Kalay N, Basar E, Ozdrogu I, ER O, Cetinkaya Y, Dogan A, et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. JACC 2006;48:2258-62. (Pubitemid 44855419)
14. Santos DL, Moreno AJM, Leino RL, Froberg MK, Wallace KB. Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy. Toxicol Appl Pharmacol 2002;185:218-27. (Pubitemid 36062795)
15. Cardinale D, Sandri MT, Martinoni A, Tricca A, Lamantia G, Cinieri S, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. JACC 2000;36:517-22.
16. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy. JACC 2010;55:213-20.
17. Ewer MS, Vooletich MT, Durand J, Woods ML, Davis JR, Valero V, et al. Reversibility of traztuzumab-related cardiotoxicity: New insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6. (Pubitemid 46657379)
18. Ewer SM, Ewer MS. Cardiotoxicity profile of traztuzumab. Drug Saf 2008;31:459-67.
19. Schwartz RG, McKenzie WB, Alexander J, Sager P, Manatunga A, Schwartz PE, et al. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Am J Med 1987;82:1109-18.
20. McKillop JH, Bristow MR, Goris ML, Billingham ME, Bockemuehl K. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity. Am Heart J 1983;106:1048-56. (Pubitemid 14229682)
21. Ewer MS, Ali MK, Mackay B, Wallace S, Valdivieso M, Legha SS, et al. A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin. J Clin Oncol 1984;2:112-7. (Pubitemid 14152453)
22. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-22.
23. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant traztuzumab therapy. J Am Coll Cardiol 2011;57:2263-70.
24. Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2007;97:318-26.
25. Gabrielson KL, Mok GS, Nimmagadda S, Bedja D, Tsao A, Wang Y, et al. Detection of dose response in chronic doxorubicin- mediated cell death with cardiac technetium 99m annexin V single-photon emission computer tomography. Mol Imaging 2008;3:132-8.
26. http://www.cancer.org/acs/groups/content/@nho/documents/document/ f861009final90809pdf.pdf. Accessed 25 Jan 2012.
27. http://www.gene.com/gene/products/information/pdf/herceptinprescribing. pdf. Accessed 25 Jan 2012.
28. van Royen N, Jaffe CC, Krumholz HM, Johnson KM, Lynch PJ, Natale D, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol 1996;77:843-50. (Pubitemid 26143494)
29. Mitani I, Jain D, Joska TM, Burtness B, Zaret B. Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. J Nucl Cardiol 2003;10: 132-9. (Pubitemid 36503798)
30. Salerno M. Multi-modality imaging of diastolic function. J Nucl Cardiol 2010;17:316-27.
31. Muntinga HJ, van den Berg F, Knol HR, Niemeyer MG, Blanksma PK, Louwes H, et al. Normal values and reproducibility of left ventricular filling parameters by radionuclide angiography. Int J Card Imaging 1997;13:165-71.
32. Lee KJ, Southee AE, Bautovich GJ, Freedman B, McLaughlin AF, Rossleigh MA, et al. Normalised radionuclide measures of left ventricular diastolic function. Eur J Nucl Med 1989;15:123-7. (Pubitemid 19080484)
33. Kusuoka H, Futaki S, Koretsune Y, Kitabatake A, Suga H, Kamada T, et al. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure. J Cardiovasc Pharmacol 1991;18:437-44.
34. Pelikan PCD, Weisfeldt ML, Jacobus WE, Miceli MV, Bulkley BH, Gerstenblith G. Acute doxorubicin cardiotoxicity: Functional, metabolic, and morphologic alterations in the isolated, perfused rat heart. J Cardiovasc Pharmacol 1986;8:1058-66.
35. Cottin Y, Touzery C, Coudert B, Gilles A, Walker P, Massing JL, et al. Impairment of diastolic function during short-term anthracycline therapy. Br Heart J 1995;73:61-4.
36. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic system in man. J Nucl Med 1987;28:1620-4. (Pubitemid 17158138)
37. Arimoto T, Takeishi Y, Niizeki T, Koyama Y, Okuyama H, Nozaki N, et al. Ongoing myocardial damage relates to cardiac sympathetic nervous disintegrity in patients with heart failure. Ann Nucl Med 2005;19:535-40. (Pubitemid 43161837)
38. Carrió I, Estorch M, Berná L, López-Pousa J, Tabernero J, Torres G. Indium-111-Antimyosin and Iodine-123-MIBG studies in early assessment of doxorubicin cardiotoxicity. J Nucl Med 1995;36:2044-9.
39. Lekakis J, Prassopoulos V, Athanassiadis P, Kostamis P, Moulopoulos S. Doxorubicin-induced cardiac neurotoxicity: Study with 123-labeled metaiodobenzylguanidine scintigraphy. J Nucl Cardiol 1996;3:37-41. (Pubitemid 26069595)
40. Valdés Olmos RA, ten Bokkel Huinink WW, ten Hoeve RFA, van Tinteren H, Bruning PF, van Vlies B, et al. Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy. Eur J Cancer 1995;31A:26-31.
41. Angerstein C, Behr TM, Behe M, Becker W. Kit formulation for In-111-labeled traztuzumab (Herceptin) for immunoscintigraphy of metastatic breast cancer expressing the HER2/neu receptor [abstract]. Eur J Nucl Med 2000;27:916.
42. Lub-De Hooge MN, Kosterink JG, Perik PG, Nijnuis H, Tran L, Bart J, et al. Preclinical characterization of 111-In DTPA-traztuzumab. Br J Pharmacol 2004;143:99-106.
43. Behr TM, Behe M. Traztuzumab and breast cancer [letter]. N Engl J Med 2001;345:995-6.
44. de Korte MA, de Vries EGE, Lub-de Hooge MN, Jager PL, Gietema JA, van der Graaf WTA, et al. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: A clue to uncover the mechanisms of trastuzumabrelated cardiotoxicity. Eur J Cancer 2007;43:2046-51. (Pubitemid 47380360)
45. Perik PJ, Lub-De Hooge MN, Gietema JA, van der Graaf WTA, de Korte MA, Jonkman S, et al. Indium-111-labeled traztuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24:2276-82. (Pubitemid 46630657)
46. Kaderli AA, Baran I, Aydin O, Bicer M, Akpinar T, Ozkalemkas F, et al. Diffuse involvement of the heart and great vessels in primary cardiac lymphoma. Eur J Echocardiogr 2010;11:74-6.
47. Lee JC, Platts DG, Huang YT, Slaughter RE. Positron emission tomography combined with computed tomography as an integral component in evaluation of primary cardiac lymphoma. Clin Cardiol 2010;33:106-8.
48. Weijs LE, Arsos G, Baarslag HJ, Wittebol S, de Klerk JM. Pericardial involvement in a non-Hodgkin lymphoma patient: Coregistered FDG-PET and CT imaging. Eur Heart J 2007;28:2698. (Pubitemid 350135525)
49. Nony P, Guastalla J, Rebattu P, Landais P, Lievre M, Bontemps L, et al. In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy. Chemother Pharmacol 2000;45:375-80. (Pubitemid 30217161)
50. Kenk M, Thackeray JT, Thorn SL, Dhami K, Chow BJ, Ascah KJ, et al. Alterations of pre- and post-synaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity. J Nucl Cardiol 2010;17:254-63.
51. Guendouz S, Buicuic O, Kirsch M, Benaiem N, Poulard JE, Deux JF, et al. Restrictive cardiomyopathy associated with left ventricle and left atria endocardial calcifications following chemotherapy. J Am Coll Cardiol 2011;57:1633.
52. Karabay CY, Kocabay G, Kalayci A, Zehir R, Tanboga H. Mitral regurgitation due to papillary muscle dyssynchrony during traztuzumab treatment. Cardiology 2010;117:296-300.
53. Hoffman R, von Bardelben S, ten Cate F, Borges AC, Kasprzak J, Firschke C, et al. Assessment of systolic left ventricular function: A multi-centre comparison of cineventriculography, cardiac magnetic resonance imaging, unenhanced and contrastenhanced echocardiography. Eur Heart J 2005;26:607-16. (Pubitemid 40461103)
54. Hundley WG, Kizilbash AM, Afridi I, Franco F, Peshock RM, Grayburn PA. Administration of intravenous perfluorocarbon contrast agent improves echocardiographic determination of left ventricular volumes and ejection fraction: Comparison with cine magnetic resonance imaging. J Am Coll Cardiol 1998;32:1426-32.
55. Jenkins C, Bricknell K, Hanekom L, Marwick TH. Reproducibility and accuracy of echocardiographic measurements of left ventricular parameters using real-time three-dimensional echocardiography. J Am Coll Cardiol 2004;44:878-86. (Pubitemid 39099588)
56. Bull SC, Main ML, Stevens GR, Goldman JH, Constable SA, Becher H. Cardiac toxicity screening by echocardiography in normal volunteers: A study of the effects of diurnal variation and use of a core laboratory on the reproducibility of left ventricular measurement. Echocardiography 2011;28:502-7.
57. Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJS, Cleland JGF, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance. Are they interchangeable? Eur Heart J 2000;21:1387-96. (Pubitemid 30599134)
58. Cottin Y, L'huiller I, Casasnovas O, Geoffroy C, Caillot D, Zeller M, et al. Dobutamine stress echocardiography identifies anthracycline cardiotoxicity. Eur J Echocardiogr 2000;1:180-3.
59. Wassmuth R, Lentszch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging- a pilot study. Am Heart J 2001;141:1007-13. (Pubitemid 32477014)
60. Karakurt C, Kocak G, Ozgen U. Evaluation of the left ventricular function with tissue tracking and tissue doppler echocardiography in pediatric malignancy survivors after anthracycline therapy. Echocardiography 2008;25:880-7.
61. Dorup I, Levitt G, Sullivan I, Sorensen K. Prospective longitudinal assessment of late anthracycline cardiotoxicity after childhood cancer: The role of diastolic function. Heart 2004;90:1214-6. (Pubitemid 39279916)
62. Monin JL, Monchi M, Gest V, Duval-Moulin AM, Dubois-Rande JL, Gueret P. Aortic stenosis with severe left ventricular dysfunction and low transvalvular pressure gradients: Risk stratification by low-dose dobutamine echocardiography. J Am Coll Cardiol 2001;37:2101-7. (Pubitemid 32548004)
63. Guimaraes-Filho F, Tan D, Braga J, Rodrigues A, Waib P, Matsubara B. Ventricular systolic reserve in asymptomatic children previously treated with low doses of anthracyclines. Am J Cardiol 2007;100:1303-6. (Pubitemid 47498287)
64. Bountioukos M, Doorduijn JK, Roelandt JR, Vourvouri EC, Bax JJ, Schinkel AF, et al. Repetitive dobutamine stress echocardiography for the prediction of anthracycline cardiotoxicity. Eur J Echocardiogr 2003;4:300-5. (Pubitemid 37455879)
65. Koyama J, Falk RH. Prognostic significance of strain doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010;3:333-42.
66. Correia E, Rodrigues B, Santos LF, Moreira D, Gama P, Cabral C, et al. Longitudinal left ventricular strain in hypertrophic cardiomyopathy: Correlation with nonsustained ventricular tachycardia. Echocardiography 2011;7:709-14.
67. Bansal M, Jeffriess L, Leano R, Mundy J, Marwick TH. Assessment of myocardial viability at dobutamine echocardiography by deformation analysis using tissue velocity and speckletracking. JACC Cardiovasc Imaging 2010;3:121-31.
68. Mavinkurve-Groothius AMC, Groot-Loonen J, Marcus KA, Bellersen L, Feuth T, Bökkerink JPM, et al. Myocardial strain and strain rate in monitoring subclinical heart failure in asymptomatic long-term survivors of childhood cancer. Ultrasound Med Biol 2010;36:1783-91.
69. Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with traztuzumab. Am Heart J 2009;158:294-301.
70. Jurcut R,Wildiers H, Ganame J, D'hooge J, De Backer J, Denys H, et al. Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 2008;21:1283-9.
71. Wong CY, O'Moore-Sullivan T, Leano R, Byrne N, Beller E, Marwick TH. Alterations of left ventricular myocardial characteristics associated with obesity. Circulation 2004;110:3081-7. (Pubitemid 39492002)
72. Mizayaki S, Daimon M, Mizayaki T, Onishi Y, Koiso Y, Nishizaki Y, et al. Global longitudinal strain in relation to the severity of aortic stenosis: A two-dimensional speckle tracking study. Echocardiography 2011;28:703-8.
73. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Feiner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis by two-dimensional strain imaging echocardiography. Am J Cardiol 2009;103:411-5.
74. Takamura T, Dohi K, Onishi K, Tanabe M, Sugiura E, Nakajima H, et al. Left ventricular contraction-relaxation coupling in normal, hypertrophic, and failing myocardium quantified by speckle-tracking global strain and strain rate imaging. J Am Soc Echocardiogr 2010;23:747-54.
75. Voigt JU, Arnold MF, Karlsson M, Hübbert L, Kukulski T, Hatle L, et al. Assessment of regional longitudinal myocardial strain rate derived from doppler myocardial imaging indexes in normal and infracted myocardium. J Am Soc Echoardiogr 2000;13:588-98. (Pubitemid 30418895)
76. Marwick TH, Leano RL, Brown J, Sun JP, Hoffman R, Lysansky P, et al. Myocardial strain measurement with 2-dimensional speckle tracking echocardiography. Definition of normal range. J Am Coll Cardiol Imaging 2009;2:80-4.
77. Lindqvist P, Morner S, Henein MY. Cardiac mechanisms of underlying normal exercise tolerance: Gender Impact. Eur J Appl Physiol 2011;112:451-9.
78. Lawton JS, Cupps BP, Knutsen AK, Ma N, Brady BD, Reynolds LM, et al. Magnetic resonance imaging detexts significant sex differences in human myocardial strain. Biomed Eng Online 2011;10:76.
79. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR. Appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging. J Am Coll Cardiol 2006;48:1475-97.
80. Cranney GB, Lotan CS, Dean L, Baxley W, Bouchard A, Pohost GM. Left ventricular volume measurement using cardiac axis nuclear magnetic resonance imaging. Validation by calibrated ventricular angiography. Circulation 1990;82:154-63. (Pubitemid 20216326)
81. Zagrosek A, Abdel-Aty H, Boyé P, Wassmuth R, Messroghli D, Utz W, et al. Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. J Am Coll Cardiol Imaging 2009;2:131-8.
82. Abdel-Aty H, Zagrosek A, Schulz-Menger J, Taylor AJ, Messroghli D, Kumar A, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. Circulation 2004;109:2411-6. (Pubitemid 38679560)
83. Assomull RG, Lyne JC, Keenan N, Gulati A, Bunce NH, Davies SW, et al. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Eur Hear J 2007;28:1242-9. (Pubitemid 47343853)
84. Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G, et al. Adriamycin cardiotoxicity: A survey of 1273 patients. Cancer Treat Rep 1979;63:827-34. (Pubitemid 9248185)
85. Wagner A, Marholdt H, Holly TA, Elliott MD, Regenfus M, Parker M, et al. Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study. Lancet 2003;361:374-9. (Pubitemid 36164969)
86. Marholdt H, Goedecke C, Wagner A, Meinhardt G, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: A comparison to histology and molecular pathology. Circulation 2004;109:1250-8. (Pubitemid 38379570)
87. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in traztuzumab induced cardiomyopathy. J Cardiovasc Mag Res 2008;10:5.
88. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T 1 mapping. J Am Coll Cardiol 2008;52:1574-80.
89. Maciera AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005;111:186-93. (Pubitemid 40139730)
90. Tham EB, Chow K, Spavor M, Pagano JJ, Haykowsky M, Thompson R. Degree of diffuse fibrosis measured by cardiac MRI correlates with LV remodeling in childhood cancer survivors after anthracycline chemotherapy [abstract]. J Cardiovasc Magn Reson 2011;13:P276.
91. Steel K, Broderick R, Gandla V, Larose E, Resnic F, Jerosch- Herold M, et al. Complementary prognostic values of stress myocardial perfusion and late gadolinium enhancement imaging by cardiac magnetic resonance in patients with known or suspected coronary artery disease. Circulation 2009;120:1390-400.
92. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:875-87.
93. Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:1369-74. (Pubitemid 351443083)
94. Mekinian A, Lions C, Leleu X, Duhamel A, Lamblin N, Coiteux V, et al. Prognosis assessment of cardiac involvement of systemic AL amyloidosis by magnetic resonance imaging. Am J Med 2010;123:864-8.
95. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
96. Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS, Sampaio RO, et al. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 2010;56:278-87.
97. Zhang R, Lu W, Wen X, Huang M, Zhou M, Liang D, et al. Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med 2011;52: 958-64.
98. Blankenberg F. To scan or not to scan, it is a question of timing: Technetium-99m-annexin v radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin Cancer Res 2002;8:2757-8. (Pubitemid 35025716)
99. Min P, Lim S, Kang S, Hong S, Hwang K, Chung K, et al. Targeted ultrasound imaging of apoptosis with annexin A5 microbubbles in acute doxorubicin-induced cardiotoxicity. J Cardiovasc Ultrasound 2010;18:91-7.
100. Bennink RJ, van den Hoff MJ, van Hemert FJ, de Bruin KM, Spijkerboer AL, Vanderheyden J, et al. Annexin V imaging of acute doxorubicin cardiotoxicity (apoptosis) in rats. J Nucl Med 2004;45:842-8. (Pubitemid 47618565)
101. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2171-9. (Pubitemid 33139463)
102. Westwood M, Anderson LJ, Firmin DN, et al. A single breathhold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. J Magn Reson Imaging 2003;18:33-9. (Pubitemid 36791266)
103. Dash R, Chung J, Chan T, Yamada M, Barral J, Nishimura D, et al. A molecular MRI probe to detect treatment of cardiac apoptosis in vivo. Magn Reson Med 2011;66:1152-62.
104. Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 1982;50:32-41. (Pubitemid 12084849)